Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | GFER | P55789 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.57 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005896 | 0.85 | ALDH1A1 (0.57) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL975489 | 0.84 | MAPT (1.00) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL13853439 | 0.84 | MAPT (0.51) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL28791705 | 0.83 | ALDH1A1 (0.51) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL6689700 | 0.83 | GFER (1.00) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL532030 | 0.83 | HTT (0.73) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL24891825 | 0.82 | RAB9A (0.64) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL1383637 | 0.81 | GAA (0.56) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL9382745 | 0.81 | MAPT (0.75) | KMT2AMAPTMEN1ALDH1A1KDM4E | |
| SCHEMBL13912 | 0.81 | KMT2A (0.75) | KMT2AMAPTMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415767-B1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5086055-A | Treating asthma, rhinitis, atopic dermatitis, chronic hives and conjunctivitis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-02-04 | — | — | US | disclosed |
| US-4960776-A | ANTIALLERGENS | A. H. ROBINS COMPANY, INC. (US) | 1990-10-02 | — | — | US | disclosed |
| US-4882330-A | 1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0277725-A2 | 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-08-10 | — | — | EP | disclosed |
| EP-0269383-A2 | 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | KMT2A 1528/4885MAPT 4776/4885MEN1 3661/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | KMT2A 2399/4885MAPT 4865/4885MEN1 4584/4885 |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | KMT2A 1732/4885MAPT 2713/4885MEN1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.